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Abstract
Background: Hypertension is the number one attributable risk factor for death throughout the
world and a major contributor to morbidity, mortality, and increasing health care expenditures in
the Philippines. Lack of access to outpatient antihypertensive medicines leads to avoidable disease
progression and costly inpatient admissions. We estimated the cost to the Philippine Health
Insurance Corporation (PhilHealth), which generally does not cover outpatient medicines, for
inpatient care for hypertension and its sequelae.
Methods: Using PhilHealth inpatient claims for discharges between July 1, 2002 and December 31,
2005, we describe costs to PhilHealth for hospitalizations classified by primary discharge diagnoses
into hospitalizations for hypertension; hypertensive heart and/or renal disease; other definite; and
other possible consequences of untreated hypertension and assess disease trajectory for patients
with more than one admission.
Results: PhilHealth reimbursed US $56 million for 444,628 hospitalizations for hypertension-
related diagnoses incurred by 360,016 patients during 3.5 years; 42% of admissions were for
essential or secondary hypertension; 19% for hypertensive heart or renal disease; and 39% for
other consequences of untreated hypertension. Among 60,659 patients admitted during the first
18 months of the study with a diagnosis of essential or secondary hypertension, 9% were
hospitalized again for treatment of sequelae; older individuals (vs. =< 40 years old), men,
dependents (vs. members), and those who were employed (vs. in the private membership category)
were more likely to be hospitalized again; as were those whose first admission during the study
period was for consequences of hypertension (vs. essential or secondary hypertension).
Conclusion:  Inpatient care for hypertension and its sequelae is expensive. Since many
hospitalizations may be avoided with antihypertensive pharmacologic therapy, an outpatient
medicines benefit may be one cost-effective policy option for PhilHealth.
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Background
Suboptimal blood pressure control is the number one
attributable risk factor for death throughout the world [1].
More than a quarter of the world's adult population,
nearly 1 billion, had hypertension in the year 2000, and
this prevalence has been estimated to increase to 29%, or
1.56 billion, by 2025 [2]. Approximately 7.1 million
deaths per year may be attributable to hypertension [1].
Hypertension has become a major contributor to morbid-
ity, mortality, and increased health care expenditures in
the Philippines. Two out of 10 Filipinos above 20 years of
age, an estimated 7.76 million in 2003, have diagnosed
hypertension [3]. Sixty-one deaths per 100,000 Filipinos
were attributed to hypertension in 1996 [4]. If not prop-
erly treated, hypertension leads to strokes, heart attacks,
heart failure, and/or kidney disease [5]. Hypertension is
amenable to lifestyle changes for some patients but often
requires life-long treatment with one or more antihyper-
tensive medications. Medication treatment of hyperten-
sion can reduce the incidence of stroke (by about
35%–40%), heart attack (by 20%–25%), and heart failure
(by more than 50%) [6] and thus prevent costly inpatient
care for complications due to disease progression.
Given the low socio-economic status of most Filipinos –
48% of the population lives on less than US $2 per day [7]
– and the high cost of medications in the country [8], reg-
ular use of antihypertensive medicines is not affordable
for many patients. However, similar to other developing
and transitional countries, the Philippines has made a
commitment to health insurance coverage for the coun-
try's population [9,10]. The Philippine Health Insurance
Corporation (PhilHealth) insures about half of the popu-
lation, who are eligible through four membership catego-
ries with different contribution structures: formally
employed workers, indigents, retirees, and individually
paying members [10]. PhilHealth currently reimburses for
inpatient care of its members (and their dependents), on
a capitated basis with caps set for each type of service
(room and board, medicines, laboratory services, physi-
cian fees, and operating room fees) by hospital category
(primary, secondary, tertiary) and case severity (depend-
ing on hospital type, up to four levels of severity) [11]. For
example, in 2006, the maximum reimbursement for a 3-
day hospital stay in a primary care hospital for a case with
low severity but use of daily general and specialist care was
US $75; the maximum reimbursement for the most com-
plicated case treated for three days of generalist and spe-
cialist non-surgical care at a tertiary care hospital was US
$1443 [11]. The number of reimbursable hospital days is
limited to 45 days per member per year and another 45
days per year to be shared by the member's dependents.
PhilHealth provides very limited outpatient benefits (for
maternal care and tuberculosis treatment) which do not
include medication coverage for chronic conditions.
Lack of access to outpatient medicines may lead to avoid-
able disease progression and costly inpatient admissions
to treat hypertension and its sequelae. The present study
aims to estimate current costs to PhilHealth for inpatient
care of hypertension. Specifically, we assessed how much
PhilHealth paid in total, per hospitalization, and per
patient per year for inpatient care of members hospital-
ized with hypertension or its sequelae. We also character-
ized high cost members who incurred multiple
admissions for hypertension or its sequelae during the 3.5
year follow-up period and assessed the progression of
their hypertensive disease over time.
Methods
We extracted from PhilHealth inpatient claims files all
hospital claims reimbursed by PhilHealth with discharge
dates between July 1, 2002 and December 31, 2005 and a
primary discharge diagnoses of essential or secondary
hypertension or conditions that could result from
untreated hypertension (Table 1). We classified possible
sequelae of hypertension into hypertensive heart and/or
renal disease; other definite consequences of untreated
hypertension, including heart attacks and strokes; and
other possible consequences of untreated hypertension,
which included some forms of ischemic heart disease and
non-traumatic intracranial haemorrhage. We excluded
from our main analyses all hospitalizations with primary
discharge diagnoses of cardiac conditions coded as I50,
I51.4–I51.9, and of renal disease coded as N00, N01,
Table 1: Classification of PhilHealth claims by primary diagnosis ICD-10 codes
Disease Category Diagnosis Codes
Essential or secondary HTN Primary diagnosis = I10 or I15; with or without other diagnoses
Hypertensive heart and/or renal disease Primary diagnosis = I11; I12; I13; with or without other diagnoses
Other definite consequences of untreated HTN Primary diagnosis = I20.0; I20.8; I20.9; I21; I22; I23; I25; I34.0; I42.0; I42.1; I42.2; I42.9; I46; I47.2; 
I48; I61; I63; I64; I65; I66; I67.0; I67.2; I67.4; I67.8; I69.1; I69.3; I69.4; I70; I71; I72; I73.9; I74; 
N28.0; with or without other diagnoses
Possible consequences of untreated HTN Primary diagnosis = I24; I49.9; I62.9; I69.2; I77.9; I78.9; I79.8; N27; with or without other 
diagnoses
HTN = hypertensionBMC Health Services Research 2008, 8:161 http://www.biomedcentral.com/1472-6963/8/161
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N02, N03, N04, N05, N06, N07, N18, N19, N26, because
these codes should not be used to indicate heart and renal
diseases among hypertensive patients. However, because
use of ICD-10 codes may not be consistent with the stated
exclusions, we separately provide calculations of the
number and costs of hospitalizations associated with
these codes.
Claims were extracted electronically from the central Phil-
Health data base after they had been adjudicated and the
approved amount had been reimbursed. PhilHealth
claims contain patient information (identification
number, name, address, age, gender, member/dependent
status, membership category); admission and discharge
dates; primary and up to two secondary diagnoses (coded
with International Classification of Diseases 10th edition
(ICD-10) codes) [12]; hospital type (public or private)
and location; a case severity indicator (ordinary, intensive,
or catastrophic), which is based on ICD-10 codes and the
service capability of the accredited provider and used to
determine maximum payment amounts [13]; and the
reimbursed amounts for different hospital services (room
and board, medicines, professional fees, laboratory, and
operating room costs). Claims data also contain amounts
billed by hospitals for each service. Personal identifiers
were removed from the data. The Institutional Review
Boards of Harvard Pilgrim Health Care and PhilHealth
approved the study.
We analyzed claims data in total and at hospitalization
and member level, and describe hospitalization frequency
and costs reimbursed by PhilHealth by primary discharge
diagnosis category. For the subset of patients who had a
hypertension-related hospitalization during the first 18
months of the study, we describe hospitalization fre-
quency, costs, and trajectory of disease development over
the rest of the follow-up period and estimated the odds of
subsequent HTN-related hospitalizations using logistic
regression analyses (SAS® version 9.1).
Results
Characteristics of hospitalizations
Between July 2002 and December 2005, PhilHealth reim-
bursed hospitals for 444,628 admissions for hyperten-
sion-related diagnoses incurred by 360,016 patients
(Table 2). Hospitalizations for essential or secondary
hypertension accounted for the largest proportion (42%)
of hospitalizations, followed by hospitalizations for defi-
nite consequences of untreated hypertension (37%).
Overall, most reimbursed hospitalizations occurred
among patients 60–79 years old; among government and
private sector employees; and in private hospitals. The
majority of hospitalizations (60%) were classified as ordi-
nary, which have the lowest reimbursement limit (Table
2).
Costs of hospitalizations
PhilHealth reimbursed US $56 million to hospitals for
hypertension-related care during 3.5 years (Table 3), 34%
of the total amount claimed by hospitals for this care. The
largest part of the total reimbursement (34%) was spent
on medicines administered in the hospital. Median cost
per hospitalization was US $74 overall, with the lowest
median cost ($57) for hospitalizations for essential or sec-
ondary hypertension. Hospitalizations for hypertensive
heart and renal disease (median cost of $68) accounted
for 15% of hypertension-related expenditures, while hos-
pitalizations for other definite sequelae of hypertension
(median cost of $130) accounted for the largest share of
expenditures (60%).
Since use of ICD-10 codes is not uniform, we also esti-
mated the total number and costs of hospitalizations for
cardiac and renal conditions coded with ICD-10 codes
that should not be used for hypertensive patients: 14,893
patients incurred 16,890 hospitalizations for cardiac dis-
eases at a cost to PhilHealth of US $2,658,140, while
12,220 patients incurred 114,786 hospitalizations for
renal diseases (including chronic renal failure) at a cost of
US $7,267,556.
Repeat hospitalizations
Among 141,103 patients who were discharged with any
HTN-related diagnosis during the first 18 months of the
study (July 2002 to December 2003), most (80%) had
only one hospitalization during the 3.5 year follow-up
period, but 20% had at least one other hospitalization.
Seven hundred and eight patients (0.5%) incurred 6 or
more hospitalizations during the 3.5 years, which consti-
tuted more than 5% of hospitalizations among those with
sufficient follow-up time for repeat hospitalizations
(Table 4). Median hospitalization costs were higher for
patients with multiple admissions: $85 for patients with
one hospitalization increasing to $1,151 for those with 10
or more hospitalizations (Table 4). Controlling for age,
gender, member status and membership category,
patients hospitalized for sequelae of hypertension during
the first 18 study months had higher odds of re-hospitali-
zation during the study period compared to those hospi-
talized for treatment of essential or secondary
hypertension (hypertensive heart and renal disease OR
1.16, 95% CI 1.12, 1.21; other definite or possible seque-
lae of hypertension OR 1.12, 95% CI 1.09, 1.15) (Table
5).
Among the 60,659 patients who were admitted during the
first 18 months of the study with a diagnosis of essential
or secondary hypertension, 9% were hospitalized again
within the study period for treatment of sequelae. Median
time to first re-hospitalization for sequelae ranged from
178 days to 255 days after the first observed hospitaliza-BMC Health Services Research 2008, 8:161 http://www.biomedcentral.com/1472-6963/8/161
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tion for essential or secondary hypertension (Table 6). For
these patients, the odds of readmission were higher
among older patients compared to younger; dependents
compared to members; and government employees and
self-employed members compared to privately employed
members; and lower for women compared to men; and
sponsored/indigent members compared to privately
employed members (Table 5).
Discussion
With almost half a million hospitalizations for hyperten-
sion-related conditions costing PhilHealth US $56 mil-
lion, the burden of inpatient care for treating
hypertension and its sequelae and the burden of cost to
PhilHealth are substantial. Of the total burden of cost,
medicines administered during inpatient stays constituted
the largest component of PhilHealth's reimbursement.
A large proportion of hospitalizations (42%, or 185,636
hospitalizations) were for essential hypertension (ICD-10
code I10). These hospitalizations can usually be pre-
vented through appropriate treatment in ambulatory care.
Disease progressed within less than one year to the point
where hospitalization for sequelae was experienced by 9%
of patients with essential and secondary hypertension
hospitalized earlier in the study period, for a total of
Table 2: Characteristics (n, %) of hypertension-related hospitalizations reimbursed by PhilHealth
All HTN-Related 
Diagnoses
Essential or 
Secondary HTN
Hypertensive 
Heart and/or Renal 
Disease
Other Definite 
Consequences of 
Untreated HTN
Other Possible 
Consequences of 
Untreated HTN
Hospitalizations, n 444628 186013 86588 166646 5381
Unique patients, n 360016 166794 67469 144415 5161
mAge group*, n 444528 185991 86566 166591 5380
0 – 3 9 8 . 11 1 . 84 . 9 5 . 51 1 . 6
40–59 37.8 45.1 35.7 30.8 32.6
60–79 46.0 37.7 50.1 53.3 44.7
80–100 8.1 5.4 9.3 10.5 11.1
Gender, n 444617 186006 86587 166643 5381
Men 46.7 38.9 46.0 55.8 47.5
Women 53.3 61.1 54.1 44.2 52.4
Member status, n 444617 186013 86588 166646 5381
Member 49.5 46.3 50.5 52.5 50.0
Dependent 50.5 53.7 49.5 47.5 50.0
Membership category, 
n
444628 186013 86588 166646 5381
Government 
employee
33.6 35.7 33.2 31.4 32.6
Private firm 
employee
31.0 30.6 27.7 33.0 32.1
Self-employed 10.8 10.4 13.5 9.8 9.6
Retired/pensioner 13.2 9.7 16.2 15.5 13.9
Sponsored/indigent 11.5 13.6 9.4 10.3 11.8
mHospital type, n 435910 181480 85108 164159 5163
Public 24.8 24.0 22.8 26.9 22.0
Private 75.2 76.0 77.2 73.1 78.0
mHospital location†, n 443703 186013 86588 165786 5316
NCR 20.4 12.0 20.5 29.9 17.3
North 18.9 20.7 17.3 17.5 27.1
Central 37.8 40.2 40.3 34.1 31.4
South 22.9 27.2 21.8 18.6 24.2
Length of stay – total 
(days) – median
1834589 3 549741 2 305705 2 957101 4 22042 3
mMedical case type, n 444628 186013 86588 166646 5381
Catastrophic 14.7 1.3 21.1 26.2 14.6
Intensive 25.9 9.1 22.8 45.9 36.6
Ordinary 59.5 89.6 56.1 28.0 48.8
Surgery performed, n 444628 186013 86588 166646 5381
No 93.9 98.5 84.6 93.4 96.3
Yes 6.1 1.5 15.4 6.6 3.7
mSome claims were missing data for this variable; *Based on age at admission date; †Location variables refer to major areas of the Philippines; HTN 
= hypertensionBMC Health Services Research 2008, 8:161 http://www.biomedcentral.com/1472-6963/8/161
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almost 7,000 additional hospitalizations. With appropri-
ate ambulatory care, many of the sequelae of hyperten-
sion could be prevented and hospitalizations for such
sequelae avoided.
Our study has several limitations, all of which are likely to
result in underestimates of the number of hospitalizations
and costs of care. The classification of hospital claims
relies on ICD-10 diagnosis codes entered at the billing
hospital. These codes may not accurately reflect the condi-
tion for which a patient was treated during the hospitali-
zation. We conservatively classified hospitalizations
based on primary discharge diagnoses to include only
hospitalizations with hypertension or sequelae as the pri-
mary reason for care. While inclusion of hypertension
diagnoses in secondary diagnosis fields may have
reflected more correctly the prevalence of hypertension
among the study population, it would likely have led to
overestimation of costs of inpatient care for hypertension,
by including costs for primary reasons of admission other
than hypertension. We also focused our main analyses on
diagnosis codes specific for essential or secondary hyper-
tension and hypertensive heart and/or renal disease,
excluding codes for heart and renal diseases which could
be sequelae of hypertension but for which other codes
should be used. If even a small percentage of the more
than 100,000 hospitalizations with primary diagnosis
chronic renal failure (ICD-10 code N18) occurred among
patients with hypertension and were attributable to the
progression of the disease, the estimates of costs of care
Table 3: Hypertension-related hospitalization costs* reimbursed by PhilHealth
Cost Categories All HTN-Related 
Diagnoses
Essential or 
Secondary HTN
Hypertensive 
Heart and/or Renal 
Disease
Other Definite 
Consequences of 
Untreated HTN
Other Possible 
Consequences of 
Untreated HTN
Total Costs Reimbursed
Total 55629906 13266422 8504060 33109546 749878
Median 74 57 68 130 84
Interquartile range (47, 136) (40, 81) (44, 112) (72, 252) (52, 151)
Room & board
Total 12144111 3490435 1903868 6598794 151013
Median 17 15 17 29 17
Interquartile range (11, 31) (9, 24) (10, 30) (16, 51) (11, 31)
Medicines
Total 18891088 3743671 2812965 12060518 273935
Median 20 12 19 40 25
Interquartile range (8, 49) (6, 26) (7, 37) (15, 99) (10, 58)
Laboratory
Total 15981484 4045645 2464490 9247897 223452
Median 26 17 20 36 32
Interquartile range (14, 36) (9, 32) (12, 36) (18, 76) (15, 42)
Operating room
Total 741670 86718 151197 494819 8937
Median 0 0 0 0 0
Interquartile range (0, 0) (0, 0) (0, 0) (0, 0) (0, 0)
Professional fee
Total 5205156 1530813 867739 2743100 63505
Median 9 7 9 11 10
Interquartile range (6, 14) (5, 11) (6, 13) (6, 20) (5, 15)
* in 2005 US$, using mid-year exchange rates and adjusted for inflation; HTN = hypertensionBMC Health Services Research 2008, 8:161 http://www.biomedcentral.com/1472-6963/8/161
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reimbursed by PhilHealth for hypertensive patients would
be substantially higher.
Because of the limited follow-up time for our study, we
underestimate the incidence of sequelae of hypertension
over time. Further studies are warranted of the natural
Table 5: Predictors of subsequent hospitalizations among PhilHealth members
Characteristic Subsequent admissions for HTN-related 
conditions among those admitted for any HTN-
related condition N = 141,384
Subsequent admissions for HTN-related 
conditions among those admitted for essential or 
secondary HTN N = 60,646
OR 95% CI OR 95% CI
Illness Category
Hypertensive heart or 
renal disease
1.16 1.12, 1.21 n/a n/a
Definite or possible 
consequences
1.12 1.09, 1.15 n/a n/a
Essential/secondary 
HTN
--n / a n / a
Age group (years)
80+ 1.80 1.68, 1.94 3.55 3.03, 4.15
60–79 1.47 1.38, 1.56 2.65 2.34, 3.00
40–59 1.86 1.75, 1.97 1.92 1.70, 2.17
< =  4 0 ----
Gender
Female 1.08 1.05, 1.11 0.84 0.79, 0.89
M a l e ----
Membership Status
Dependent 1.05 1.02, 1.09 1.12 1.05, 1.19
M e m b e r ----
Membership category
Government-employee 1.20 1.16, 1.24 1.14 1.07, 1.22
Self-employed 1.56 1.49, 1.64 1.15 1.03, 1.29
Retired 3.78 3.60, 3.96 1.06 0.93, 1.21
Sponsored/indigent 0.95 0.89, 1.01 0.87 0.77, 0.98
P r i v a t e  f i r m  e m p l o y e e ----
Predictors of subsequent hospitalizations during 3.5 years among PhilHealth members with an admission for any and for essential or secondary HTN 
during the first 18 months of the study (July 2002–December 2003)
Table 4: Hospitalization frequency and costs among PhilHealth members with any HTN-related discharges
Per Member Number of 
Hospitalizations in 3.5 Years
Number (%) of Members 
n = 141103
Number (%) of 
Hospitalizations n = 189010
Total Costs for Hospitalizations and 
Costs per Member in 3.5 Years (PhP) 
Total Sum Median Interquartile Range
1 112107 (79.5) 112107 (59.3) 161222657
85
(54, 157)
2 20637 (14.6) 41274 (21.8) 5906369
188
(119, 341)
3–5 7651 (5.4) 25807 (13.7) 3375467
308
(198, 547)
6–9 479 (0.3) 3301 (1.8) 330315
498
(336, 849)
10+ 229 (0.2) 6521 (3.5) 346820
1151
(684, 1979)
Distribution of number of hypertension-related hospitalizations and associated costs (*in 2005 US$, using mid-year exchange rates and adjusted for 
inflation) in 3.5 years for PhilHealth members with an admission during the first 18 months of the study (July 2002–December 2003)BMC Health Services Research 2008, 8:161 http://www.biomedcentral.com/1472-6963/8/161
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progression of hypertension in the Philippines and the
downstream costs of failing to control the illness among
outpatients.
Our study is based on data from claims submitted to and
paid for by PhilHealth. PhilHealth provides first-dollar
coverage for up to 45 days of hospitalization per year for
members and up to 45 days per year to be shared among
dependents [11]. Claims data allowed us to calculate the
amount billed by hospitals to PhilHealth and the amount
reimbursed by PhilHealth for inpatient care of patients
hospitalized for hypertension treatment. The large differ-
ence between billed and reimbursed amounts – Phil-
Health reimbursed 34% of what was billed – accounts for
denied parts of or entire claims but does not consider
costs for which claims were never submitted. Therefore,
the data do not allow us to estimate the overall cost of
care, particularly for sicker patients, who reached the max-
imum reimbursement for care during a hospitalization or
who required more than 45 hospital days during a given
year and needed to pay for additional care out-of-pocket.
End-stage renal disease patients, for example, require 3
days of hospitalization per week for dialysis; for those, we
only captured the first 45 hospitalization days per year. In
addition, we are not able to observe costs among patients
unable to afford the out-of-pocket share of hospitaliza-
tion who chose not to present for needed care.
Claims data also do not allow us to assess the impact of
hypertension and sequelae on patients and their families.
In addition to the negative physical and emotional conse-
quences, patients suffer losses in income due to hospital-
izations; incur expenses for paying for inpatient care when
maximum reimbursement limits are reached; and may
lack affordable access to outpatient medicines that would
prevent a worsening of their disease.
Antihypertensive pharmacological therapy has a major
impact on health [14]. The higher the blood pressure, the
greater is the risk of heart attack, stroke, and kidney dis-
ease [5]. Anti-hypertensive medication treatment drasti-
cally reduces these risks by between 20% (for heart
attacks) and more than 50% (for heart failure) [6]. How-
ever, patients can only adhere to pharmaceutical therapy
for chronic disease when they can afford it. In 2005, one
month of treatment with a beta-blocker (atenolol) pur-
chased in a private pharmacy cost the equivalent of 3 days
of wages of the lowest paid government worker (254
pesos in 2005); one month of treatment with an angi-
otensin-converting enzyme inhibitor (captopril) cost the
equivalent of 6 days wages [8]. Many Filipinos do not
have the resources of the lowest paid government worker:
14% of the country's 87 million people live on less than
$1 per day [15] and 48% live on less than $2 per day [7].
Data from the United States show a 26% reduction in use
of antihypertensives when patient copayments for the
drugs were doubled and suggest that reducing patients'
out-of-pocket costs could increase the use of preventive
cardiovascular medications [16]. In fact, recent analyses of
costs and benefits of combination pharmacotherapy for
secondary prevention after a myocardial infarction among
U.S. patients suggest that providing the medications for
free (without co-payments) would reduce mortality and
reinfarction rates and save $5,974 per patient [17].
In addition to assuring that appropriate diet and exercise
are recommended in ambulatory care, an outpatient med-
icines benefit to facilitate access to affordable antihyper-
tensives could be one policy option to reduce PhilHealth
costs for inpatient care for patients with hypertension.
One hospitalization for hypertensive heart and/or renal
disease costs PhilHealth $68, which could buy thiazide
Table 6: Hospitalization trajectory among PhilHealth members with discharges for essential or secondary HTN
Sequelae Number (%) of 
Members n = 60659
Number (%) of 
Hospitalizations N = 
78109
Days to First Hospital Readmission for Sequelae
25th Percentile 50th Percentile 75th Percentile
Hypertensive heart disease 1948 (3.2) 2297 (2.9) 85 247 496
Hypertensive renal disease 110 (0.2) 411 (0.5) 60 255 502
Hypertensive heart and 
renal disease
26 (0.0) 26 (0.0) 68 178 367
Other definite 
consequences of untreated 
HTN
3292 (5.4) 3919 (5.0) 59 225 496
Other possible 
consequences of untreated 
HTN
154 (0.3) 163 (0.2) 80 211 437
Reasons for subsequent hypertension-related hospitalization during 3.5 years for PhilHealth members with an admission for essential or secondary 
HTN during the first 18 months of the study (July 2002–December 2003) HTN = hypertensionBMC Health Services Research 2008, 8:161 http://www.biomedcentral.com/1472-6963/8/161
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treatment at private retail prices (2005 US $6.19/month)
for one patient for 11 months, not considering the lower
prices which PhilHealth should be able to negotiate for
covered outpatient medicines. An outpatient medicines
benefit would also allow PhilHealth to improve quality of
care by reimbursing for antihypertensive therapy that fol-
lows standard treatment guidelines.
Designing and implementing an outpatient medicines
benefit would require careful consideration and under-
standing of the population of potential beneficiaries; the
extent of the benefit; the logistics of implementation; and
of its costs and benefits. A pilot study could answer a series
of critical questions related to the feasibility, sustainabil-
ity, and impacts of such a benefit. How could potential
beneficiaries of this benefit be identified? Which type,
quantity, and frequency of medicines would PhilHealth
subsidize, for which members, in part or in whole? How
would PhilHealth contract with pharmacies to supply the
medications? Could adherence to treatment guidelines be
enforced? How could misuse of the benefit be detected
and avoided? PhilHealth and its collaborators have begun
the design of this type of outpatient medicines benefit
pilot study. The goals of this work are to improve access to
affordable medicines and to improve the health of an
increasing number of Filipinos with chronic conditions
covered by PhilHealth.
Conclusion
Inpatient care for hypertension and its sequelae is costly
for PhilHealth. Many hospitalizations should be avoided
with continued ambulatory antihypertensive pharmaco-
logic therapy. Our study raises questions as to whether
PhilHealth members have access to appropriate outpa-
tient treatment of hypertension, and whether an outpa-
tient medicines benefit may be one policy option for
PhilHealth to decrease inpatient admissions and costs.
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